Cargando…

The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial

OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, David, Ibrahim, Fowzia, Hill, Harry, Tom, Brian, Prothero, Louise, Baggott, Rhiannon R., Bosworth, Ailsa, Galloway, James B., Georgopoulou, Sofia, Martin, Naomi, Neatrour, Isabel, Nikiphorou, Elena, Sturt, Jackie, Wailoo, Allan, Williams, Frances M.K., Williams, Ruth, Lempp, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390769/
https://www.ncbi.nlm.nih.gov/pubmed/32931984
http://dx.doi.org/10.1016/j.semarthrit.2020.07.014
_version_ 1783564509790601216
author Scott, David
Ibrahim, Fowzia
Hill, Harry
Tom, Brian
Prothero, Louise
Baggott, Rhiannon R.
Bosworth, Ailsa
Galloway, James B.
Georgopoulou, Sofia
Martin, Naomi
Neatrour, Isabel
Nikiphorou, Elena
Sturt, Jackie
Wailoo, Allan
Williams, Frances M.K.
Williams, Ruth
Lempp, Heidi
author_facet Scott, David
Ibrahim, Fowzia
Hill, Harry
Tom, Brian
Prothero, Louise
Baggott, Rhiannon R.
Bosworth, Ailsa
Galloway, James B.
Georgopoulou, Sofia
Martin, Naomi
Neatrour, Isabel
Nikiphorou, Elena
Sturt, Jackie
Wailoo, Allan
Williams, Frances M.K.
Williams, Ruth
Lempp, Heidi
author_sort Scott, David
collection PubMed
description OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. METHODS: A 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. RESULTS: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. INTERPRETATION: The trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms.
format Online
Article
Text
id pubmed-7390769
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-73907692020-07-30 The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial Scott, David Ibrahim, Fowzia Hill, Harry Tom, Brian Prothero, Louise Baggott, Rhiannon R. Bosworth, Ailsa Galloway, James B. Georgopoulou, Sofia Martin, Naomi Neatrour, Isabel Nikiphorou, Elena Sturt, Jackie Wailoo, Allan Williams, Frances M.K. Williams, Ruth Lempp, Heidi Semin Arthritis Rheum Article OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. METHODS: A 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. RESULTS: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. INTERPRETATION: The trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms. W.B. Saunders 2020-10 /pmc/articles/PMC7390769/ /pubmed/32931984 http://dx.doi.org/10.1016/j.semarthrit.2020.07.014 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Scott, David
Ibrahim, Fowzia
Hill, Harry
Tom, Brian
Prothero, Louise
Baggott, Rhiannon R.
Bosworth, Ailsa
Galloway, James B.
Georgopoulou, Sofia
Martin, Naomi
Neatrour, Isabel
Nikiphorou, Elena
Sturt, Jackie
Wailoo, Allan
Williams, Frances M.K.
Williams, Ruth
Lempp, Heidi
The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title_full The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title_fullStr The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title_full_unstemmed The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title_short The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
title_sort clinical effectiveness of intensive management in moderate established rheumatoid arthritis: the titrate trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390769/
https://www.ncbi.nlm.nih.gov/pubmed/32931984
http://dx.doi.org/10.1016/j.semarthrit.2020.07.014
work_keys_str_mv AT scottdavid theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT ibrahimfowzia theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT hillharry theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT tombrian theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT protherolouise theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT baggottrhiannonr theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT bosworthailsa theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT gallowayjamesb theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT georgopoulousofia theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT martinnaomi theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT neatrourisabel theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT nikiphorouelena theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT sturtjackie theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT wailooallan theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT williamsfrancesmk theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT williamsruth theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT lemppheidi theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT scottdavid clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT ibrahimfowzia clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT hillharry clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT tombrian clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT protherolouise clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT baggottrhiannonr clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT bosworthailsa clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT gallowayjamesb clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT georgopoulousofia clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT martinnaomi clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT neatrourisabel clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT nikiphorouelena clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT sturtjackie clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT wailooallan clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT williamsfrancesmk clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT williamsruth clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial
AT lemppheidi clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial